Combination chemotherapy with vindesine, etoposide, and cisplatin in non-small cell lung cancer

A pilot study of the Southeastern Cancer Study Group

J. D. Hainsworth, L. L. Porter, D. H. Johnson, K. R. Hande, S. N. Wolff, R. Birch, G. Enas, F. A. Greco

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Ninety-two patients with advanced non-small cell lung cancer were treated with a combination chemotherapy regimen containing cisplatin, vindesine, and etoposide. Eighteen patients (20%) achieved major responses to therapy (three complete responders and 15 partial responders). Response rates were similar in each histologic subtype. Initial performance status was an important determinant of response; 42% of the patients with a Karnofsky performance status ≥70% responded versus 5% of those with a performance status <50%. The median duration of partial response was 21 weeks; complete responders had a median response duration of 50 weeks. The median survival for the entire group was 23.5 weeks. Toxicity with this regimen was acceptable; myelosuppression was the major toxic effect and was severe in only 10% of the patients. This regimen produced response rates comparable to those reported with other combinations containing cisplatin. Survival advantage in patients receiving this treatment is not established.

Original languageEnglish (US)
Pages (from-to)339-341
Number of pages3
JournalCancer Treatment Reports
Volume70
Issue number3
StatePublished - 1986

Fingerprint

Vindesine
Etoposide
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Cisplatin
Neoplasms
Karnofsky Performance Status
Survival
Poisons
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combination chemotherapy with vindesine, etoposide, and cisplatin in non-small cell lung cancer : A pilot study of the Southeastern Cancer Study Group. / Hainsworth, J. D.; Porter, L. L.; Johnson, D. H.; Hande, K. R.; Wolff, S. N.; Birch, R.; Enas, G.; Greco, F. A.

In: Cancer Treatment Reports, Vol. 70, No. 3, 1986, p. 339-341.

Research output: Contribution to journalArticle

Hainsworth, J. D. ; Porter, L. L. ; Johnson, D. H. ; Hande, K. R. ; Wolff, S. N. ; Birch, R. ; Enas, G. ; Greco, F. A. / Combination chemotherapy with vindesine, etoposide, and cisplatin in non-small cell lung cancer : A pilot study of the Southeastern Cancer Study Group. In: Cancer Treatment Reports. 1986 ; Vol. 70, No. 3. pp. 339-341.
@article{fd98a261af5748549bad7dc87ca8d59a,
title = "Combination chemotherapy with vindesine, etoposide, and cisplatin in non-small cell lung cancer: A pilot study of the Southeastern Cancer Study Group",
abstract = "Ninety-two patients with advanced non-small cell lung cancer were treated with a combination chemotherapy regimen containing cisplatin, vindesine, and etoposide. Eighteen patients (20{\%}) achieved major responses to therapy (three complete responders and 15 partial responders). Response rates were similar in each histologic subtype. Initial performance status was an important determinant of response; 42{\%} of the patients with a Karnofsky performance status ≥70{\%} responded versus 5{\%} of those with a performance status <50{\%}. The median duration of partial response was 21 weeks; complete responders had a median response duration of 50 weeks. The median survival for the entire group was 23.5 weeks. Toxicity with this regimen was acceptable; myelosuppression was the major toxic effect and was severe in only 10{\%} of the patients. This regimen produced response rates comparable to those reported with other combinations containing cisplatin. Survival advantage in patients receiving this treatment is not established.",
author = "Hainsworth, {J. D.} and Porter, {L. L.} and Johnson, {D. H.} and Hande, {K. R.} and Wolff, {S. N.} and R. Birch and G. Enas and Greco, {F. A.}",
year = "1986",
language = "English (US)",
volume = "70",
pages = "339--341",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Combination chemotherapy with vindesine, etoposide, and cisplatin in non-small cell lung cancer

T2 - A pilot study of the Southeastern Cancer Study Group

AU - Hainsworth, J. D.

AU - Porter, L. L.

AU - Johnson, D. H.

AU - Hande, K. R.

AU - Wolff, S. N.

AU - Birch, R.

AU - Enas, G.

AU - Greco, F. A.

PY - 1986

Y1 - 1986

N2 - Ninety-two patients with advanced non-small cell lung cancer were treated with a combination chemotherapy regimen containing cisplatin, vindesine, and etoposide. Eighteen patients (20%) achieved major responses to therapy (three complete responders and 15 partial responders). Response rates were similar in each histologic subtype. Initial performance status was an important determinant of response; 42% of the patients with a Karnofsky performance status ≥70% responded versus 5% of those with a performance status <50%. The median duration of partial response was 21 weeks; complete responders had a median response duration of 50 weeks. The median survival for the entire group was 23.5 weeks. Toxicity with this regimen was acceptable; myelosuppression was the major toxic effect and was severe in only 10% of the patients. This regimen produced response rates comparable to those reported with other combinations containing cisplatin. Survival advantage in patients receiving this treatment is not established.

AB - Ninety-two patients with advanced non-small cell lung cancer were treated with a combination chemotherapy regimen containing cisplatin, vindesine, and etoposide. Eighteen patients (20%) achieved major responses to therapy (three complete responders and 15 partial responders). Response rates were similar in each histologic subtype. Initial performance status was an important determinant of response; 42% of the patients with a Karnofsky performance status ≥70% responded versus 5% of those with a performance status <50%. The median duration of partial response was 21 weeks; complete responders had a median response duration of 50 weeks. The median survival for the entire group was 23.5 weeks. Toxicity with this regimen was acceptable; myelosuppression was the major toxic effect and was severe in only 10% of the patients. This regimen produced response rates comparable to those reported with other combinations containing cisplatin. Survival advantage in patients receiving this treatment is not established.

UR - http://www.scopus.com/inward/record.url?scp=0022585623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022585623&partnerID=8YFLogxK

M3 - Article

VL - 70

SP - 339

EP - 341

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 3

ER -